Cerebrolysin: What the Evidence Actually Shows

Cerebrolysin is a mixture of low-molecular-weight peptides and free amino acids enzymatically derived from porcine brain tissue, used clinically for stroke, traumatic brain injury, and dementia across Russia, Eastern Europe, China, and other Asian and post-Soviet countries — but it has never been an FDA-approved product in the United States. Unlike most of the compounds in this site's non-board corpus, it is not a research-chemical-market invention with zero human data: it has one of the largest real clinical-trial literatures of any compound this site covers. Reading that literature directly, indication by indication, tells a more mixed story than either "proven" or "unstudied."

What it actually is

Cerebrolysin is manufactured by enzymatic hydrolysis of porcine brain proteins, yielding a standardized mixture of peptide fragments and free amino acids with reported neurotrophic and neuroprotective properties in preclinical models¹. It ships as a ready-mixed liquid solution for injection, not a lyophilized powder — confirmed directly against the manufacturer's own current product listing, which describes it as a "Solution for injection" at a fixed concentration. Every major clinical trial's dosing description matches that: patients are infused with a stated volume (commonly 30 mL) of pre-mixed solution, not a reconstituted vial.

Stroke: the largest trial ever run found no benefit on its own primary endpoint

CASTA, the largest Cerebrolysin randomized controlled trial to date, enrolled 1070 acute ischemic stroke patients across Asia and reported its result plainly: "the confirmatory end point showed no significant difference between the treatment groups²." A post hoc subgroup of the most severely affected patients showed a favorable mortality trend — the trial's own authors called this "an observation [that] should be confirmed by a further clinical trial," not an established finding. The 2023 Cochrane review, the seventh update of a review running continuously since 2010, pooled seven RCTs (1773 participants total) and reached a harder conclusion than CASTA alone: "moderate-certainty evidence indicates that Cerebrolysin or Cerebrolysin-like peptide mixtures... probably have no beneficial effect on preventing all-cause death"³. The same review reports something CASTA's abstract does not: a statistically significant increase in non-fatal serious adverse events at the standard 30 mL/10-day dosing regimen (risk ratio 2.39, 95% CI 1.10 to 5.23). It also states directly, in its own words, that "the manufacturer of Cerebrolysin supported three multicentre studies, either totally, or by providing Cerebrolysin and placebo, randomisation codes, research grants, or statisticians¹" — a documented industry-funding relationship across a meaningful share of the stroke evidence base, reported by the Cochrane authors themselves.

Traumatic brain injury: a genuinely different, more positive picture

The TBI literature does not read the same way. The CAPTAIN trial series — two prospective, randomized, placebo-controlled phase IIIb/IV trials totaling 185 patients with moderate-to-severe TBI — found a statistically significant "small-to-medium" effect favoring Cerebrolysin on a composite functional/neuropsychological outcome measure at both 30 and 90 days³. A separate 2023 systematic review pooling 10 studies (8749 patients, both retrospective and prospective) reports a statistically significant improvement in Glasgow Coma Scale and Glasgow Outcome Scale scores, while explicitly noting "mortality of any cause and the length of stay was not affected by the treatment⁴." Read the two indications side by side rather than averaged together: real, moderate-certainty evidence of no mortality benefit and a genuine safety signal in stroke; a smaller but statistically real functional-outcome benefit in TBI, on different scales, with mortality unaffected there too.

The U.S. regulatory picture: no history of any kind

Checked live for this article, Cerebrolysin has no FDA compounding-nomination history at all — a different fact pattern from Selank and Thymosin Alpha-1, the other two Russian/international-research compounds in this same five-compound batch. FDA's current 503A Bulks List (updated May 14, 2026, fetched fresh) contains no Cerebrolysin match in Category 1, 2, or 3⁵. FDA's companion significant-safety-risk page, fetched live, has no Cerebrolysin entry either⁶. DailyMed's structured-product-label search returns zero results, confirming no FDA-approved U.S. product exists under this name⁷. openFDA's FAERS database returns 80 total reports for "CEREBROLYSIN"⁸ — a real reporting volume, consistent with genuine clinical use abroad rather than a research-chemical curiosity with no track record.

What this means if you're considering it

None of the 31 providers this site's own reviews cover sell Cerebrolysin — this site's own identity-layer research confirms it is not tagged to any reviewed seller. It is not sold as a lyophilized vial in the same research-chemical channels as this corpus's other calculator molecules, and it ships pre-mixed as a ready-to-use solution, which is why no /calculator/cerebrolysin reconstitution page exists on this site despite the compound genuinely being an injectable. Its evidence base is real and substantial by this corpus's standards, but it does not point one direction: the largest stroke trial ever run found no benefit on its own primary endpoint, and a 2023 Cochrane review — noting a documented manufacturer-funding relationship across several of the pooled trials — found no mortality benefit alongside a real increase in non-fatal serious adverse events, while a smaller TBI trial series found a statistically significant functional benefit on a different outcome measure. If you're researching other cognitive/neuroprotective compounds this site covers, our Noopept evidence review covers a much smaller, oral small molecule with a thinner and less industry-entangled human trial record — a genuinely different evidence shape than Cerebrolysin's own.